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Guidelines and Guidance 
Systematic Reviews of Genetic 
Association Studies
Gurdeep S. Sagoo, Julian Little, Julian P. T. Higgins*
The past decade has witnessed growing interest in genetic predisposition to common diseases, and along with rapid advancements in high-throughput 
genotyping technology, has resulted in a tremendous amount 
of published epidemiological evidence on gene-disease 
associations. Reported genetic associations with common 
diseases have become numerous and are mostly of small 
magnitude [1]. With this growth in evidence has come an 
increasing need to collate and summarize the evidence in 
order to identify true genetic associations among the large 
volume of false positives [2]. Convincing evidence of true 
association therefore requires careful control over potential 
biases and chance effects. Control over bias is important 
both in study design [3] and in considering the selective 
availability of data on associations that have been examined 
[4]. Because most genetic associations are small, large 
sample sizes are necessary for their detection, especially when 
many genetic variants are investigated simultaneously, as in 
genome-wide association studies. Furthermore, replication of 
findings in independent data sets is now widely regarded as 
a prerequisite for convincing evidence of association. Thus, 
multiple studies from several independent groups exist.
Systematic reviews and meta-analyses have become a 
common approach to summarize gene-disease associations 
[5]. However, as apparently inconsistent results and 
interpretations of syntheses of evidence on the same genetic 
association have been reported [6], it is useful to lay out issues 
in the methods and conduct of these types of research studies. 
The Human Genome Epidemiology Network (HuGENet) has 
developed “HuGE reviews” (typically systematic reviews) as the 
cornerstone of an online resource containing the cumulative 
and changing information on epidemiologic aspects of human 
genes [7]. Many of these contain meta-analyses, or statistical 
syntheses of the findings from multiple studies. In this article, 
we describe some key components of the methodology for 
undertaking systematic reviews and meta-analyses of genetic 
association studies. Detailed discussions of these issues and 
further recommendations can be found in the HuGE Review 
Handbook [8] (see also Box 1). Additional detailed guidance 
on conducting systematic reviews is available in the Cochrane 
Handbook for Systematic Reviews of Interventions [9] and 
The Handbook of Research Synthesis [10].
Why Systematic Reviews?
Traditional (narrative) reviews are subjective, and as such 
have a number of disadvantages that lead them to being more 
prone to bias and error [11]. Narrative reviews rarely state 
how studies were selected for inclusion, how (or whether) 
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Summary Points
preferable to narrative reviews, since they make the processes 
more transparent.
the systematic review should be stated in advance, ideally by 
writing a protocol.
than one bibliographic database, as well as sources of grey 
literature such as online data repositories.
least two people; primary study authors should be contacted 
for missing data or for issues that are unclear from reports.
although convincing evidence of what study characteristics 
are most important is lacking.
performed where possible and appropriate, acknowledging 
any heterogeneity and the potential for bias within included 
studies (e.g., poor validity, selective reporting) and in the data 
set as a whole (e.g., publication bias). Studies (rather than 
reports) should be the unit of analysis, to ensure data are not 
double-counted.
The Guidelines and Guidance section contains advice on conducting and reporting 
medical research.
PLoS Medicine  |  www.plosmedicine.org 0240 March 2009  |  Volume 6  |  Issue 3  |  e1000028
their quality was assessed, or how the findings from multiple 
studies were synthesized in order to draw conclusions. This 
can lead to a review that supports and reinforces the author’s 
view, which can be misleading. In contrast, systematic reviews 
are designed as rigorous research studies. They allow a more 
objective appraisal of the evidence than a narrative review 
by aiming to identify, critique, and synthesize evidence from 
all relevant existing studies on the topic in question using 
predefined methods. Figure 1 outlines the general processes 
involved in a systematic review.
Data for systematic reviews are typically collated primarily 
from publications, often supplemented by data from 
correspondence with authors of the original studies. In 
the field of human genome epidemiology, however, the 
ability to look at increasing numbers of markers prevents 
the publication of summary data for each genetic variant 
in a traditional journal format. A variety of sources may 
therefore be used, including the published literature, online 
supplementary materials, online databases, and study authors. 
An increasingly popular technique is the meta-analysis of 
individual participant data through the collaboration of a 
consortium of investigators. This is likely to minimize bias 
compared with a literature-based systematic review, but 
possibly at the expense of precision, since a comprehensive 
systematic review may include evidence from studies that 
are not involved in the consortium. The two approaches are 
complementary to one another, and some of their potential 
advantages and disadvantages are summarized in Table 1.
Preparation of a Protocol
Like other research studies, systematic reviews should ideally 
be carefully planned with a detailed protocol prepared in 
advance. Producing a protocol with criteria predefined 
for study selection will minimize any selection bias based 
on study results. Such a protocol should therefore clearly 
formulate the review question, explain the rationale for 
conducting such a review, define a priori eligibility criteria 
for study inclusion, describe the methods for conducting a 
comprehensive search for studies, indicate the methods for 
assessing study validity and relevance, and state whether a 
meta-analysis is planned and describe the methodology to be 
used for conducting such an analysis.
Objectives and Eligibility Criteria
The objectives of a systematic review of genetic association 
studies will typically be (i) to identify all epidemiological 
doi:10.1371/journal.pmed.1000028.g001
Figure 1: Process of a Systematic Review
Box 1: Development of This Guidance
The guidance in this paper stems primarily from the Human 
Genome Epidemiology Network (HuGENet) HuGE Review 
Handbook. This document arose from a two-day discussion 
workshop held in Cambridge, United Kingdom, on November 
2–3, 2004. In attendance were 27 participants with expertise in 
genetic epidemiology, clinical medicine, public health, meta-
analysis, systematic review methods, searching, and statistical 
methods. The discussions built on previous iterations of 
guidance from the HuGENet Executive Committee. Speakers at 
the workshop were asked to comment on current methods, on 
empirical evidence currently available to guide methods, and 
on current uncertainties. A writing committee was appointed 
to produce the Handbook, under the editorship of Julian Little 
and Julian Higgins. The Handbook was influenced heavily by the 
Cochrane Handbook for Systematic Reviews of Interventions, 
which has a long history of evolution and is also based on 
empirical evidence where available.
The guidance has been updated for this paper to reflect 
developments in technology and methodology. Gurdeep 
Sagoo was invited to join to bring a new perspective, given his 
experience of undertaking HuGE systematic reviews. Passages 
about genome-wide association studies were added at the 
request of the current journal editors and are based on the 
consensus of the authors. The development of the guidance 
benefits from being the broad consensus (in 2004 to 2006) of 
numerous individuals with an interest in systematic reviews, but 
does not claim to be authoritative or to reflect the current views 
of all people listed below.
Writing Group for the HuGE Review Handbook
Molly Bray, Julian Higgins, John Ioannidis, Muin Khoury, Julian 
Little, Teri Manolio, Liam Smeeth, Jonathan Sterne.
Participants at the 2004 Workshop
Betsy Anagnostelis, Adam Butterworth, John Danesh, Carol 
Dezateux, Doug Easton, John Gallacher, Marta Gwinn, Julian 
Higgins, John Ioannidis, Muin Khoury, Sarah Lewis, Julian Little, 
Teri Manolio, David Melzer, Cosetta Minelli, Paul Pharoah, 
Georgia Salanti, Simon Sanderson, Liam Smeeth, Lesley 
Smith, Jonathan Sterne, Donna Stroup, Emanuela Taioli, John 
Thompson, Simon Thompson, Neil Walker, Ron Zimmern.
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investigations of the associations of interest; (ii) to assess 
the validity of the evidence; (iii) to determine whether an 
association exists; (iv) to assess whether associations are 
consistent across studies in magnitude and direction; and 
(v) to quantify the likely magnitude of an association if it 
exists. Associations of interest have in the past usually been 
identified through biological plausibility, although candidate 
associations are now frequently identified from genome-wide 
association studies. 
The applicability of a systematic review depends on the 
selection of appropriate studies to be included in it. Eligibility 
criteria for the review, defined a priori, should allow relevant 
studies investigating the gene(s), allelic variant(s), disease(s), 
clinical subtypes, and any other outcomes of interest (such 
as molecular biomarkers) to be easily identifiable and 
included in the review. Appropriate study designs and study 
populations should also be considered in order to allow the 
reliable assessment of associations and interactions.
Searching for Eligible Studies
A key characteristic of a systematic review is a comprehensive 
search. Limiting a review to studies identified only from 
MEDLINE (or PubMed) is usually insufficient, for two 
reasons. First, any review restricted to published literature is 
prone to publication bias, whereby only a subset comprising 
the most “publishable” findings are available from the totality 
of evidence on a particular genetic association. Thus, sources 
beyond the published literature should be examined. Second, 
even within the published literature, reporting bias may 
be present whereby studies with different conclusions are 
published in different types of journals. MEDLINE is just 
one of several major sources of bibliographic information. 
These biases may, to some extent, be reduced by searching 
comprehensively for studies available through other sources. 
Other bibliographic databases likely to be useful for genetic 
association studies include EMBASE and the Science Citation 
Index. Overlap between these various databases is far from 
complete; for example, of approximately 4,800 journals 
indexed in EMBASE, 1,700 are not indexed in MEDLINE 
(see Chapter 6 in [9]). The implications of this incomplete 
overlap for genetic association studies are not clear. 
Furthermore, bibliographic searches may still not retrieve all 
articles that are in the indexed journals [12].
Further sources that might be searched include reference 
lists of study reports and review articles, Web sites, theses, 
books, reports, and online databases (including data 
repositories for genome-wide and other association studies 
[13]). Sources other than peer-reviewed journals are often 
referred to as “grey literature.”
Once the searches have been undertaken, the records 
identified need to be assessed against the eligibility criteria 
for the review. A typical example of the process from search 
to selection is illustrated in Figure 2.
Minimizing Human Error 
All reasonable attempts should be made to prevent the 
introduction of errors and personal biases. An important 
attribute of systematic reviews is that criteria for study 
inclusion are clearly prespecified. This is perhaps the 
most notable difference between a narrative review and a 
systematic review. Independent duplication of steps in the 
review process, such as selection of studies, extraction of data, 
and critical assessment of methods used in the individual 
studies, can further reduce biases and minimize errors. 
Accidental omission of data, or accidental duplication of a 
study in a meta-analysis, may lead to spurious false-negative or 
false-positive findings.
Assessing Validity of Each Study
The validity of a meta-analysis depends on the validity of 
the studies included within it, so it is important that each 
component study is appraised before being included. 
Because effect magnitudes in genetic association studies are 
generally small (i.e., odds ratio < 1.2), even small biases may 
be important. The most important sources of bias in genetic 
association studies are less well understood than those in 
other study designs such as randomized trials. Extensive 
discussions of potential biases are available, with the principal 
candidates being case definition, population stratification 
(confounding due to sub-populations in the sample that 
differ both in genotype prevalence and disease risk), and 
methods in the collection, handling, and processing of 
DNA and the determination of genotypes (including 
blinding to case-control status) [3,14]. Little empirical 
evidence associating study results with study characteristics 
for genetic association studies exists as yet, however. This 
evidence will perhaps be most reliably derived from meta-
epidemiological studies, in which results of studies with 
different characteristics are compared within meta-analyses, 
and findings are synthesized across meta-analyses to enhance 
power [15,16].
The appraisal of potential biases is difficult in practice, 
not only because of the uncertainty over which study 
characteristics are important, but also because of 
incomplete or variable reporting of the methods used in 
the studies themselves [17]. Initiatives such as the STREGA 
(STrengthening the REporting of Genetic Association 
Studies) statement, which offers guidelines for reporting 
Table 1: Data Sources for Meta-Analysis of Genetic Association Studies
Approach Advantages Disadvantages
Literature-based systematic review Low resource requirements. Can be prone to serious bias due to selective 
availability of published data.
Literature-based systematic review and liaison with 
investigators
Relatively low resource requirements. May be prone to bias due to selective availability of 
published data.
Consortium-based meta-analysis of existing data Data not subject to selective availability; potential to 
harmonize data.
Data may be incomplete; inclusion in consortium 
may be related to findings.
Consortium-based meta-analysis with prospective 
genotyping
Complete data; availability of data unrelated to findings; 
ability to harmonize methods.
Genotyping costs.
doi:10.1371/journal.pmed.1000028.t001
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of individual genetic association studies, may improve the 
situation in the future.
Assessing Bias in the Review as a Whole
In addition to potential biases in the individual studies, 
attention should be paid to bias in the collection of studies as 
a whole. Two particular considerations are reporting biases 
and bias in the selection of genetic variants to study. 
Reporting biases include both publication bias, which 
typically refers to suppression of evidence concerning 
an entire study on the basis of its findings, and selective 
reporting, whereby only the most exciting findings are 
reported. Selective reporting of only the most promising 
variants is a natural consequence of an attempt to summarize 
an association study of many genetic markers within the 
constraints of a traditional paper journal article. To overcome 
these constraints, association studies are increasingly 
exploiting Web-based publication for complete findings, 
although in practice there are often obstacles to prevent this 
occurring.
The possibility of reporting biases can only be discarded 
if it is known that all eligible data from all eligible studies 
are available (or if a truly unbiased subset of these data 
is available). It is difficult to imagine situations in which 
reviewers are confident that all existing studies are either 
known or reported without bias. The most reliable way 
to overcome these biases is therefore in the prospective 
generation of data, for example by using a consortium-based 
approach.
It is also helpful to keep in mind that the very act of 
investigating a gene-disease association may be dependent 
on earlier results. Even in a world of flawless studies that are 
completely reported, it is likely that the most exciting findings 
are those that are targets for replication. Initial exciting 
findings may well be chance effects, and so situations in which 
a meta-analysis is contemplated (those in which multiple 
studies exist) comprise a biased subset of possibly important 
associations. There is good evidence of the exaggerated 
effect that is often seen in the earliest report of an association 
compared with subsequent attempts to replicate the finding 
[18].
Meta-Analysis
Meta-analysis is the statistical synthesis of results from 
multiple studies [19]: an example is provided in Figure 3 
[20]. When implemented and interpreted appropriately, 
and applied to unbiased and correctly analyzed studies, it 
provides a powerful tool to understand both similarities and 
differences in results from multiple studies. By exploiting 
the totality of evidence, meta-analyses offer enhanced 
power to detect associations and increased precision in the 
estimation of their magnitude. Meta-analyses are encouraged 
doi:10.1371/journal.pmed.1000028.g002
Figure 2: A Typical Process for Searching and Assessing Eligibility of Studies
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in systematic reviews. However, attention should always be 
paid to the possibility of reporting biases in reviews based on 
published literature. Furthermore, it is important that each 
entry in a meta-analysis represents an independent sample of 
data. Thus for example, multiple reports of the same study 
need to be merged to obtain a single “best” answer for that 
study prior to inclusion in the meta-analysis.
Most meta-analyses are undertaken by calculating weighted 
averages of the estimates from multiple studies. A metric is 
chosen for the analysis that ensures comparable quantities 
with reasonable statistical properties. For example, log odds 
ratios are typically combined for case-control studies (and 
then presented as odds ratios). If quantitative traits are 
measured using different methods across studies, they may be 
standardized before pooling, usually by expressing the results 
in terms of standard deviations. 
Consistency of results across studies should always be 
evaluated, and can be achieved using a statistical test of 
homogeneity or by quantifying the between-study variance 
(or quantities derived from these such as I 2, which describes 
the proportion variation in point estimates that is due to 
heterogeneity rather than within-study error [21]). Potential 
reasons for variation in findings across studies should also 
be investigated. To minimize unreliable consequences from 
multiple testing, potential sources of variation in study results 
should be limited in number and prespecified whenever 
possible. Consideration should be given to using methods to 
temper the statistical significance of findings based on a small 
number of studies [22].
Sensitivity analyses are to be encouraged, to ensure that 
findings are robust. For example, undue influence of the 
initial study, of smaller studies, or of studies with potential 
biases may be responsible for inappropriate conclusions. 
Furthermore, the choice of statistical model (or method) 
or the inclusion of studies with uncertain eligibility for the 
systematic review may affect the results, and robustness to 
these should also be evaluated.
Meta-analysis methods of gene-disease association studies 
closely follow well-developed methodology for randomized 
trials [4,6,23]. Due to so-called “Mendelian randomization” 
in the transmission of genetic material from parents to 
children, confounding is generally thought to be of minimal 
concern (although not ignorable, since it may arise through 
population stratification). Thus, unadjusted analyses are 
common in meta-analyses, even if matched studies have 
adjusted for matching factors such as age and sex. 
doi:10.1371/journal.pmed.1000028.g003
Figure 3: Example of a Forest Plot
The plot shows the relation between N-acetyltransferase (NAT1) acetylation status (slow or rapid) and bladder cancer risk (data from Sanderson et al. 
[20]). The classification of acetylation phenotype is made either directly, by measuring the metabolism of a probe drug, or indirectly, by measuring the 
genotype associated with that phenotype.
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The era of genome-wide association studies has 
implications for the meta-analysis of genetic associations. 
Although, in principle, summary data for the variant(s) 
of interest in the review should be sought from available 
genome-wide association studies in the same way as they 
are sought from candidate gene studies, in practice many 
genome-wide association studies are designed primarily for 
detecting associations rather than quantifying them, and 
the potential for bias must be assessed. Furthermore, the 
variant(s) of interest might not have been included in a 
genome-wide scan. While it is possible that some unknown 
genotypes could be imputed, proposed methods typically 
require detailed data [24], and it is unclear whether a more 
naive approach, based on minimal summary data and linkage 
disequilibrium information, would be appropriate.
Other special considerations in the meta-analysis of 
gene-disease associations are discussed in detail elsewhere 
and include the choice of inheritance model [25,26], the 
treatment of Hardy-Weinberg equilibrium [27,28], and the 
combination of associations for markers known to be in 
linkage disequilibrium [29]. Developments in the last area are 
now allowing complex syntheses of data across whole-genome-
wide association studies [30].
Presenting and Interpreting Results
A systematic summary of all available evidence should 
allow the strengths and gaps in the evidence base to be 
identified and allow recommendations to be made in order 
to stimulate research to address such gaps. The magnitude 
of the association between the allelic variants and the clinical 
outcomes studied in terms of relative and attributable risks in 
different populations should be summarized in a systematic 
and concise way. Comments should also be provided on the 
quality and methodology of studies. Tables should summarize 
information on each gene-disease association study (possibly 
online as Web-based supplements, depending on size and 
journal formats). Table 2 lists some of the characteristics 
most likely to be relevant. If a meta-analysis is conducted, 
these should usually be presented as forest plots as in Figure 
3. Statistics related to heterogeneity (e.g., between-study 
variance or I 2 and confidence intervals) and investigations of 
bias should be presented. Multiple subgroup and sensitivity 
analyses are conveniently presented as “overview” forest plots 
without including the individual studies.
A discussion of the results should also address issues such 
as the overall quantity and quality of the evidence base, the 
consideration of possible publication and selective reporting 
biases, the likelihood that associations are causal, and any 
potential public health applications. For example, results 
from small or few studies should be interpreted with great 
caution, as it is common to see dissipation of early claimed 
effects [31], and early studies have no predictive power 
for the subsequent picture of the evidence [32]. Interim 
guidance is available to assess the strength of evidence that 
an observed association is genuine [33]. These criteria assess 
the three domains of precision (i.e., through sample size), 
consistency of results across studies (i.e., through meta-
analytic measures of heterogeneity), and protection from bias 
both within and across studies in a meta-analysis. 
Additional detailed guidance for the general reporting of 
systematic reviews and meta-analyses are available from PRISMA 
(Preferred Reporting Items for Systematic Reviews; formerly 
known as QUOROM) [34]. Reporting guidance for meta-
analyses of observational studies are also available from MOOSE 
(Meta-analysis Of Observational Studies in Epidemiology) [35].
Concluding Remarks
The strengths and limitations of systematic reviews are well 
established for clinical trials, largely through the efforts of 
The Cochrane Collaboration [36]. They are increasingly 
being applied to observational studies, and currently there 
are as many meta-analyses of observational data conducted 
as there are of clinical trials. The citation impact of both 
types of meta-analyses is equally high, the highest among all 
study designs in the health sciences [37]. The principal value 
of a well-conducted systematic review of genetic association 
studies is in establishing reliably the presence and magnitude 
of individual gene-disease associations. By complementing 
both consortium-based pooled analyses and larger-scale 
attempts to collate genetic association evidence across whole 
fields, they play an important role alongside other research 
designs in the integration of evidence on genetic association 
[5]. At their most ambitious, systematic reviews and meta-
analyses can collate evidence across all studied genetic 
variants for a phenotype, with notable examples provided by 
three databases of genetic association evidence for Alzheimer 
disease, Parkinson disease, and schizophrenia that include ad 
hoc meta-analyses [38–40].
Table 2: Characteristics Likely To Be of Interest for Each Study Included in a Review
Study Details Genotypes and Other 
Exposures
Population Phenotypes Findings Source of Data
ID (e.g., first author)







(including blinding of 
researchers)
City or area and country
Health/disease status
Setting
Sample sizes (cases and 










Clinical subtypes of 
interest
Genotype data for 
cases and controls, as 
presented in the study 
report
Measures of association 
(e.g., odds ratios and 95% 
confidence intervals)
Interactions reported
All references (clearly 
linking multiple 
publications from the 
same study)
State if data taken 
direct from publication, 
from online 
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Within the Summary Points we summarize our key 
suggestions for methodology of systematic reviews of genetic 
association studies. These reflect our accumulated experience 
to date and are not intended to lay down standards for 
universal application. This is an area of rapid development. 
In a decade’s time, appropriate methods for the collation and 
integration of evidence on gene-disease association may be 
substantially different. 
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